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Background: Subviral particles of hepatitis B virus (HBV) composed of L protein deletion variants with the 48
N-terminal amino acids of preS joined to the N-terminus of S protein (1-48preS/S) induced broadly neutralizing
antibodies after immunization of mice with a Semliki Forest virus vector. A practical limitation for use as vaccine is
the suboptimal secretion of such particles. The role of the N-terminal preS myristoylation in the cellular retention of
full-length L protein is described controversially in the literature and the relation of these data to the truncated L
protein was unknown. Thus, we studied the effect of preS myristoylation signal suppression on 1-48preS/S secretion
efficiency, glycosylation and subcellular distribution.
Findings: The findings are that 1-48preS/S is secreted, and that removal of the N-terminal myristoylation signal in
its G2A variant reduced secretion slightly, but significantly. The glycosylation pattern of 1-48preS/S was not affected
by the removal of the myristoylation signal (G2A mutant) but was different than natural L protein, whereby N4 of
the preS and N3 of the S domain were ectopically glycosylated. This suggested cotranslational translocation of
1-48preS in contrast to natural L protein. The 1-48preS/S bearing a myristoylation signal was localized in a compact,
perinuclear pattern with strong colocalization of preS and S epitopes, while the non-myristoylated mutants
demonstrated a dispersed, granular cytoplasmic distribution with weaker colocalization.
Conclusions: The large deletion in 1-48preS/S in presence of the myristoylation site facilitated formation and
secretion of protein particles with neutralizing preS1 epitopes at their surface and could be a useful feature for
future hepatitis B vaccines.
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Hepatitis B virus (HBV) contains three closely related
transmembrane proteins in its lipid envelope. The S pro-
tein comprises the common C terminus of all three
HBV surface (HBs) proteins and is the main structural
component of the viral envelope. The nonessential M
protein contains a preS2 N-terminal extension of 55
amino acids (aa), while the essential L protein has a fur-
ther N terminal extension of 108 or 119 aa, termed
preS1 [1]. The preS1 domain contains at its N-terminus* Correspondence: baiba@biomed.lu.lv
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distribution, and reproduction in any mediuman essential attachment site of HBV to infection-suscep-
tible cells [2] while the preS2 sequence seems to have
no essential function in the viral life cycle beyond acting
as a spacer in the L protein [3]. HBs proteins are se-
creted from infected, transfected, or transduced cells as
20–22 nm spherical or filamentous, noninfectious lipo-
protein particles.
During translation, the preS domain (i. e. preS1 +
preS2) of L protein remains unglycosylated and in the
cytosol whereas the S domain is partially N-glycosylated
and assumes a topology at the endoplasmatic reticulum
(ER) with at least two transmembrane passes [4]. How-
ever, in a posttranslational maturation step approxima-
tely 50% of the preS domains are translocated to thed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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surface of the secreted HBV or subviral particles while
the cytosolic domains remain within the particles [5-7].
Full length L protein alone in absence of the S protein is
not secreted from transfected cells [8-10]. The retention
of L protein depends on the cytosolic localization of
preS1 [11], but N-terminal shortening of the preS se-
quence by more than 110 aa (or 98 aa in HBV genotype
D) finally leads to its cotranslational translocation to the
ER [11] governed by the signal peptide I [4] of the S do-
main, N-glycosylation of the residual preS sequence [12]
and secretion of subviral particles.
The 48 aa N-terminal part of preS1 carries HBV-
neutralizing epitopes [2,13] while the C-terminal part
does not [14]. Furthermore the C-terminal part in its
cytosolic orientation prevents secretion [15]. These
observations led to the design of expression vectors en-
coding the N-terminal part of preS1 linked with the S
protein for the generation of potential HBV vaccines
[16,17]. Using replication-deficient Semliki Forest vi-
rus (rSFV) vectors, we could express the neutralization-
relevant preS1 part linked to the S domain of HBs
subviral particles and consequently use these vectors for
immunization of mice [18]. The influence of the large
internal deletion in the L protein on its structure and
topology was not yet known. Therefore, we analyzed the
cellular localization, the N-glycosylation pattern of
expressed 1-48preS/S protein variants, and the surface
exposure of the shortened preS1 domain on the subviral
particles.
Furthermore, secretion of the subviral particles from
the transduced cells was found to be a limiting factor
in our previous study. Therefore, we searched for ways
to improve the secretion of the HBs particles. The
N–terminus of the L protein is modified by myristate at
Gly 2 of preS1 [19]. Kuroki et al. [20] found that my-
ristoylation alone did not cause retention, but Prange
et al. reported the opposite [21]. More recently, Abou-
Jaoude et al. [22] studied the secretion and infectivity
of hepatitis delta virus variants with and without N-
terminal myristoylation of L and other HBV envelope
proteins. They found no detectable influence of the my-
ristoylation on the secretion of these viruses but could
show that infectivity was lost after inactivation of the
myristoylation signal in L protein. It was not clear how
these findings could be applied to the context of the 1-
48preS/S particles with a heavily truncated preS domain.
Thus, it appeared useful to determine whether inacti-
vation of the myristoylation signal would improve se-
cretion of the 1-48preS/S protein and allow for surface
exposure of the preS1 epitopes. Exchange of Gly2 to Ala
(G2A) disrupts the myristoylation motif Met-Gly recog-
nized by N-myristoyl transferase [23] and this mutation
was introduced in an expression vector for generationof L protein deletion variants without a myristoylation
signal.
Results and discussion
Generation of rSFV vector plasmids (pSFV1) encoding
the 1-48preS/S variants with the myristic acid attach-
ment site have been described [18]. Its variant with Gly
2 substituted to Ser (pSFV1-G2S 1-48preS/S) (Figure 1A)
was generated by amplification of the corresponding
gene from the plasmid pFD Pr[13–59]S (kindly provided
by K. Sasnauskas) by forward primer 50 GACACAGATC
TGCCGCCACCATGTCTCAGAATCTTTCCAC 30; the
G2A variant (pSFV1-G2A 1-48preS/S) (Figure 1A) was
generated by forward primer 50 GACACAGATCTGCC
GCCACCATGGCCCAGAATCTTTCCAC 30 from plas-
mid pFD GlyPr[13–59] (gift from K. Sasnauskas). The
reverse primer for generation of both plasmids was 50
CTCTGTACCCGGGTTATTAGTGATGGTGATGGTG
ATGAATG 30. The fragments were cloned in the pSFV1
vector at the BglII and SmaI sites and insertions con-
firmed by sequencing. Replication-deficient rSFV [24]
were produced by co-electroporation of BHK-21 cells
with an in vitro transcribed vector and helper RNA.
Huh7 cells were infected with rSFV at MOI 10, cell
medium was replaced after 18 h with a fresh medium,
which was collected after 24 h and cells were lysed with
0.5% Triton X-100 lysis buffer. Cell medium and lysates
were subjected to in-house ELISAs as described [18]
with monoclonal antibodies (MAbs) MA18/7 recogni-
zing epitope DPAF of preS1 20–23 in genotype D and
C20/02 recognizing the correctly folded S domain be-
tween aa 118 and 149 (W. H. Gerlich, unpublished).
The secretion of the 1-48preS/S protein variants is
shown in Table 1. We observed a slightly but signifi-
cantly reduced secretion of the 1-48preS/S variant with
an inactivated myristoylation site (G2A or G2S) com-
pared to the unmodified variant, although the intracellu-
lar expression level of the wt and the G2S mutant was
equal (Table 1). The difference is small but the accuracy
of the immune assays used suggests that the inactivation
of the myristoylation signal had indeed a minor negative
effect on the release of the particles. The data are
compatible with the report of Abou-Jaoude et al. [22]
who did not observe a difference of HDV secretion
with or without myristoylation as detected by qualita-
tive immunoblot.
By electron microscopy of concentrated Huh7 cell
medium 22 h after infection we could confirm that the
G2S variant was released as 22 nm subviral particles
with an accessible preS1 antigen on the surface as shown
by binding of MAb MA18/7 and subsequent anti-mouse
IgG conjugated with 5 nm gold particles (Figure 2)
according to the method of Louro and Lesemann [25].
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Figure 1 A. Schematic representation of the SFV expression vectors. SP6 RNA polymerase promoter for transcription in vitro is shown by the
filled arrow. Sequences encoding 1-48preS/S variants are placed under the control of SFV 26S subgenomic promoter (empty arrow) and
expression is directed by SFV replicase. The filled triangle denotes the modified myristic acid attachment site, where Gly2 was replaced with Ala
or Ser in L deletion variants G2A 1–48preS/S and G2S 1-48preS/S. The space between the regions encoding aa 1–48 of preS1 and S/ayw2
denotes the “spacer” encoding aa LEGGSGG. B. Schematic representation of L protein deletion variants consisting of the first 48 aa of preS1 fused
to the N-terminus of the S domain showing the myristoylation and potential glycosylation sites.
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vector, Huh7 cells were transduced with rSFV encoding
full length L protein expressing also S and M (not shown)
and the secretion incompetent variant 1-48preS/S0 which
lacks the start codon of S protein [18]. In case of the
1-48preS/S0 variant, the MA18/7-specific signal from the
cell medium was barely above the cut-off (Table 1), while
no MA18/7-specific signal was found in the cell medium
of L protein transduced cells (not shown).
Western blot analysis with MA18/7 of Huh7 cell
lysates revealed three L protein-related bands at appro-
ximately 32, 35 and 38 kDa. PNGase F digestion under
denaturing conditions shifted the three bands to one
30 kDa position (Figure 3). This suggested that the
1-48preS/S variants existed as triple, double and single
N-glycosylated forms, in contrast to wt L protein which
exists in a major single glycosylated and a minor ungly-
cosylated form. The 1-48preS/S variants bear four po-
tential N-glycosylation sites: N4 in the preS1 fragment,Table 1 Secretion of L protein deletion variants
Secreted, OD492
L deletion variant MAbs
MA18/7 C20/02
1-48preS/S, myr wt 1.10 ± 0.16 1.00 ± 0.12
G2A 1-48preS/S, myr- 0.52 ± 0.06 0.56 ± 0.09
G2S 1-48preS/S, myr- 0.67 ± 0.08 0.43 ± 0.06
1-48preS/S0, myr wt 0.17 ± 0.01 0.14 ± 0.01
Huh7 cells were infected at MOI 10 with rSFV encoding respective proteins. 18 h af
This was collected after 24 h and cells were lysed with a buffer containing 0.5% Trit
phenylmethanesulfonylfluoride. Huh7 cell lysates with 5 μg/ml cell protein and 100
MAbs MA18/7 and C20/02. OD492 of cell lysates tested on mictrotiter plate coated w
proteins and therefore not shown. Mean values are shown ± SD.
* Ratios were calculated with OD492 values obtained with ELISA using MAb MA18/7
** The difference to 1-48preS/S myr wt is significant at α = 0.05.and N3, N59 and N146 in the S domain (Figure 1B).
N146 is partially used in all 3 HBs proteins [1], while N3
of the S domain or S protein is not glycosylated in nat-
ural HBs proteins. According to the transmembrane top-
ology [26], we assume that the 1-48preS/S variants are
partially glycosylated at N3 of the S domain, whereas
N59 is most probably within the cytosolic loop and not
accessible. In full-length L protein, preS is not trans-
located to the ER and should be unglycosylated [5], be-
cause preS1 lacks an N-terminal signal peptide for
cotranslational translocation [6,11]. In line with this
model, only O-glycosylation of preS2 but no preS-N-
glycosylation was found in natural L-containing HBsAg
from HBV carriers [27]. A posttranslational N-glyco-
sylation of N 4 and N112 (genotype D) in preS1was
reported more recently in full-length L protein expressed
in various transfected cell lines [26]. In contrast, the
postulated glycosylation at N4 of preS1 in the L deletion
variants studied here is in line with data obtained with LIntracellular, OD at 492 nm Ratio secreted/intracellular*
MA18/7
1.08 ± 0.08 1.06 ± 0.09
0.69 ± 0.04 0.78 ± 0.04**
1.14 ± 0.09 0.60 ± 0.06**
0.72 ± 0.10 0.25 ± 0.07
ter infection cell medium was collected and replaced with a fresh medium.
on X-100, 150 mM NaCl, 50 mM Tris–HCl pH 7.5, 2 mM EDTA and 1 μg/ml
μl of 2 ml of medium were analyzed by ELISA on microtiter plates coated with
ith C20/02 was barely above cut-off (OD at 492 nm = 0.1) for all 1-48preS/S
.
Figure 2 Electron microscopy analysis of immunogold-labelled
G2S mutant of 1-48preS/S subviral particles after reaction with
MAb MA18/7 recognizing preS1. The suspension of the particles
was adsorbed on carbon-formvar coated grids and incubated with
MAb MA 18/7, followed by anti-mouse IgG conjugated with 5 nm
gold particles (Sigma), as described [24]. The grids were negatively
stained with 2% uranyl acetate aqueous solution and examined with
a JEM-1230 electron microscope (JEOL Ltd.,Tokyo, Japan) at 100 kV.
The scale bar corresponds to 25 nm.
Figure 3 N-Glycosylation pattern of L protein deletion variants.
Huh7 cells were infected at MOI 10 with rSFV encoding 1-48preS/S,
G2A 1-48preS/S and 1-48preS/S0. Twenty hours after infection cells
were lysed with lysis buffer containing 0.5% Triton X-100, 150 mM
NaCl, 50 mM Tris–HCl pH 7.5, 2 mM EDTA and 1 μg/ml
phenylmethanesulfonylfluoride. Five-hundred U of PNGase F were
added to 10 μl of Huh7 cell lysates diluted in reaction buffer
(50 mM sodium phosphate buffer, pH 7.5) containing 1% NP40, and
incubated for 1 h at 37°C. To perform the reaction under denaturing
conditions, glycoprotein denaturing buffer was added to 10 μl of
cell lysates and incubated for 10 min at 100°C, whereas for digestion
under native conditions denaturing buffer was omitted. After
separation by SDS-PAGE, proteins were transferred to a Hybond-P
membrane in a semi-dry electro blotter. The membrane was reacted
with MAb MA18/7, followed by goat anti-mouse antibodies
conjugated with horseradish peroxidase. “+”, treated with PNGase
F; “-”, untreated.
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to discriminate between preS1 and S linked glycans,
PNGase F digestion was also performed in the absence
of glycoprotein denaturing buffer in order to preserve
the native conformation of S protein. N146-linked gly-
can is protected from digestion in the native confor-
mation of the S domain whereas preS glycans are still
removed [28]. Under these conditions, the major prod-
uct had 32 kDa, but the nonglycosylated 30 kDa product
was also observed. This suggests that the majority of
proteins is glycosylated at N146 and at one or both of
the other sites. Furthermore, it shows that at least one
site upstream of signal peptide I i. e. N3 in S or N4 in
preS1 may be occupied even in absence of glycan at
N146 in S. The glycosylation pattern of the in-frame co-
expressed S protein was not affected, S protein could be
detected in single glycosylated and unglycosylated form
for the G2A and G2S 1-48preS/S mutants. Glycosylation
of the non-secreted 1-48preS/S0 protein did not differ
from the 1-48preS/S variant. Likewise, Prange et al.
reported secretion and glycosylation at N4 of a protein
consisting of the first 41 aa of preS1 (subtype ayw)
joined N-terminally to the S protein [16].
The influence of myristoylation of L protein on secre-
tion has been found to be different in various studies
[20,22] suggesting a potential ER retention [21]. Thus,we studied the secretion of the 1-48preS/S0 variant by
inactivation of the myristoylation site but particles were
again not secreted (not shown). The N-glycosylation pat-
tern of the S0 variant was unaltered and was obviously
not related to secretion competence. Theoretically, the
postulated glycosylation at N3 of the S domain could en-
hance secretion as shown for glycosylation of M protein
[29], but this was not the case for the 1-48preS/S0 vari-
ant. Based on previous data [22] we conclude that the
major determinant of effective secretion of wt and mo-
dified L protein subviral particles is the in-frame co-
expressed S protein.
Surprisingly, presence of the myristoylation signal did
not impair the secretion of 1-48preS/S particles but im-
proved it slightly (Table 1). The somewhat better secre-
tion of these particles with the myristoylation signal is
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ports virus-like particle formation of Lassa virus [30]
and virus assembly of HIV [31]. Although, myristoyla-
tion is reported to be dispensable for virion morphogen-
esis of HBV [32], its role and mechanisms in facilitating
generation of subviral particles may be a subject of fu-
ture investigation.
Myristoylation serves as a membrane anchor for a
number of proteins [33]. To examine how mutation of
the myristoylation site affects the subcellular localization
of L protein deletion variants, BHK-21 cells were in-
fected with rSFV encoding 1-48preS1/S, G2S and G2A
mutants and were analyzed by confocal immunofluo-
rescence microscopy. Cells were stained with S specific
MAb 1-9C1 directed to a linear epitope in the S domain
followed by preS1 specific polyclonal antibodies H863.
The anti-S antibody binds to the S domain in L proteinFigure 4 Confocal microscopy analysis of 1-48preS/S, G2A 1-48preS/S
encoding the respective proteins as described in Materials and Methods se
antibodies H863 (α-preS1). The cell nuclei were stained with DAPI. Panel A
each fluorophore - FITC, TRITC and DAPI (y axis, relative numbers) along a
white arrow.deletion variants as well as to in-frame co-expressed S
protein. In rSFV-1-48preS/S transduced cells anti-S and
anti-preS1 signals were mostly localized in the peri-
nuclear area with a strong colocalization of both antigens
(Figure 4, upper panel of sections A and B). In con-
trast, the Gly2 mutants showed a dispersed localization
throughout the cell cytoplasm and a weak colocalization
of the two antigens (Figure 4 middle and bottom panels of
sections A and B). These results are in line with the matrix
protein Z of Lassa virus where mutation of N-terminal
Gly to Ala altered the subcellular localization from a
punctuate to a diffuse pattern [30]. The stronger coloca-
lization of the preS1 and S epitopes in cells transfected
with the wt variant than with the variant without my-
ristoylation signal suggests that the myristate supports the
interaction between the L protein and the S protein and
this would probably increase secretion.and G2S 1-48preS/S proteins. BHK-21 cells were infected with rSFV
ction and stained with MAb 1-9C1 (α-S), followed by polyvalent rabbit
depicts images of cells, panel B shows the fluorescence intensity of
line (x axis, μm) drawn across a selected cell which is marked by the
Niedre-Otomere et al. Virology Journal 2013, 10:63 Page 6 of 6
http://www.virologyj.com/content/10/1/63Competing interests
Authors declare that they have no competing interests.
Authors’ contributions
BNO produced rSFV vectors, performed cell infection with these vectors,
participated in the design of the study, collated and analyzed the data and
wrote the manuscript. AB performed cell infection with rSFV, immunoassays,
PNGase F digestion and Western blotting. RB performed confocal
microscopy analysis. VO provided electron microscopy images. PP revised
the manuscript and gave final approval of the version to be published. DG
and WHG participated in the design of the study, provided MAbs, assisted in
the interpretation of the results, the writing and revision of the manuscript.
TK participated in the design of the study and generation of pSFV1 plasmids
encoding L protein deletion variants. All of the authors read and approved
the final version of the manuscript.
Acknowledgements
The authors thank I. Timofejeva, A. Ose and N. Gabrusheva for the excellent
technical assistance, D. Pjanova for help with confocal microscopy images, K.
Sasnauskas for the plasmids pFD Pr [13–59] and pFD Pr [13–59]S and H.
Schaller for anti-preS1 polyvalent antibodies H863. This work was supported
by The Latvian National Research Programme 2010 – 2013 “BIOMEDICINE”,
and by the European Social Fund.
Author details
1Biomedical Research and Study Centre, Ratsupites street 1, Riga LV-1067,
Latvia. 2Institute of Medical Virology, Justus Liebig University, Schubertstr. 81,
Giessen D-35392, Germany.
Received: 11 July 2012 Accepted: 20 February 2013
Published: 25 February 2013
References
1. Heermann KH, Goldmann U, Schwartz W, Seyffarth T, Baumgarten H, Gerlich
WH: Large surface proteins of hepatitis B virus containing the pre-s
sequence. J Virol 1984, 52:396–402.
2. Glebe D, Aliakbari M, Krass P, Knoop EV, Valerius KP, Gerlich WH: Pre-s1
antigen-dependent infection of Tupaia hepatocyte cultures with human
hepatitis B virus. J Virol 2003, 77:9511–9521.
3. Ni Y, Sonnabend J, Seitz S, Urban S: The pre-s2 domain of the hepatitis B
virus is dispensable for infectivity but serves a spacer function for
L-protein-connected virus assembly. J Virol 2010, 84:3879–3888.
4. Eble BE, MacRae DR, Lingappa VR, Ganem D: Multiple topogenic
sequences determine the transmembrane orientation of the hepatitis B
surface antigen. Mol Cell Biol 1987, 7:3591–3601.
5. Bruss V, Lu X, Thomssen R, Gerlich WH: Post-translational alterations in
transmembrane topology of the hepatitis B virus large envelope protein.
EMBO J 1994, 13:2273–2279.
6. Ostapchuk P, Hearing P, Ganem D: A dramatic shift in the transmembrane
topology of a viral envelope glycoprotein accompanies hepatitis B viral
morphogenesis. EMBO J 1994, 13:1048–1057.
7. Prange R, Streeck RE: Novel transmembrane topology of the hepatitis B
virus envelope proteins. EMBO J 1995, 14:247–256.
8. Cheng KC, Smith GL, Moss B: Hepatitis B virus large surface protein is not
secreted but is immunogenic when selectively expressed by
recombinant vaccinia virus. J Virol 1986, 60:337–344.
9. Persing DH, Varmus HE, Ganem D: Inhibition of secretion of hepatitis B
surface antigen by a related presurface polypeptide. Science 1986,
234:1388–1391.
10. Ou JH, Rutter WJ: Regulation of secretion of the hepatitis B virus major
surface antigen by the preS-1 protein. J Virol 1987, 61:782–786.
11. Bruss V, Vieluf K: Functions of the internal pre-S domain of the large
surface protein in hepatitis B virus particle morphogenesis. J Virol 1995,
69:6652–6657.
12. Bruss V, Thomssen R: Mapping a region of the large envelope protein
required for hepatitis B virion maturation. J Virol 1994, 68:1643–1650.
13. Neurath AR, Seto B, Strick N: Antibodies to synthetic peptides from the
preS1 region of the hepatitis B virus (HBV) envelope (env) protein are
virus-neutralizing and protective. Vaccine 1989, 7:234–236.
14. Bremer CM, Sominskaya I, Skrastina D, Pumpens P, El Wahed AA, Beutling U,
Frank R, Fritz HJ, Hunsmann G, Gerlich WH, Glebe D: N-terminalmyristoylation-dependent masking of neutralizing epitopes in the preS1
attachment site of hepatitis B virus. J Hepatol 2011, 55:29–37.
15. Gallina A, Gazina E, Milanesi G: A C-terminal PreS1 sequence is sufficient
to retain hepatitis B virus L protein in 293 cells. Virology 1995, 213:57–69.
16. Prange R, Werr M, Birkner M, Hilfrich R, Streeck RE: Properties of modified
hepatitis B virus surface antigen particles carrying preS epitopes. J Gen
Virol 1995, 76:2131–2140.
17. Page M, Jones CD, Bailey C: A novel, recombinant triple antigen hepatitis
B vaccine (Hepacare). Intervirology 2001, 44:88–97.
18. Niedre-Otomere B, Bogdanova A, Skrastina D, Zajakina A, Bruvere R, Ose V,
Gerlich WH, Garoff H, Pumpens P, Glebe D, Kozlovska T: Recombinant
Semliki Forest virus vectors encoding hepatitis B virus small surface and
pre-S1 antigens induce broadly reactive neutralizing antibodies. J Viral
Hepat 2012, 19:664–673.
19. Persing DH, Varmus HE, Ganem D: The preS1 protein of hepatitis B virus
is acylated at its amino terminus with myristic acid. J Virol 1987,
61:1672–1677.
20. Kuroki K, Russnak R, Ganem D: Novel N-terminal amino acid sequence
required for retention of a hepatitis B virus glycoprotein in the
endoplasmic reticulum. Mol Cell Biol 1989, 9:4459–4466.
21. Prange R, Clemen A, Streeck RE: Myristylation is involved in
intracellular retention of hepatitis B virus envelope proteins. J Virol
1991, 65:3919–3923.
22. Abou-Jaoudé G, Molina S, Maurel P, Sureau C: Myristoylation signal
transfer from the large to the middle or the small HBV envelope protein
leads to a loss of HDV particles infectivity. Virology 2007, 365:204–209.
23. Farazi TA, Waksman G, Gordon JI: The biology and enzymology of protein
N-myristoylation. J Biol Chem 2001, 276:39501–39504.
24. Liljestrom P, Garoff H: A new generation of animal cell expression vectors
based on the Semliki Forest virus replicon. Biotechnology (N Y) 1991,
9:1356–1361.
25. Louro D, Lesemann DE: Use of protein A-gold complex for specific
labelling of antibodies bound to plant viruses. I. Viral antigens in
suspensions. J Virol Methods 1984, 9:107–122.
26. Lambert C, Prange R: Posttranslational N-glycosylation of the hepatitis B
virus large envelope protein. Virol J 2007, 4:45.
27. Schmitt S, Glebe D, Tolle TK, Lochnit G, Linder D, Geyer R, Gerlich WH:
Structure of pre-S2 N- and O-linked glycans in surface proteins from
different genotypes of hepatitis B virus. J Gen Virol 2004, 85:2045–2053.
28. Tolle TK, Glebe D, Linder M, Linder D, Schmitt S, Geyer R, Gerlich WH:
Structure and glycosylation patterns of surface proteins from
woodchuck hepatitis virus. J Virol 1998, 72:9978–9985.
29. Lu X, Mehta A, Dwek R, Butters T, Block T: Evidence that N-linked
glycosylation is necessary for hepatitis B virus secretion. Virology 1995,
213:660–665.
30. Strecker T, Maisa A, Daffis S, Eichler R, Lenz O, Garten W: The role of
myristoylation in the membrane association of the Lassa virus matrix
protein Z. Virol J 2006, 3:93.
31. Lindwasser OW, Resh MD: Multimerization of human immunodeficiency
virus type 1 Gag promotes its localization to barges, raft-like membrane
microdomains. J Virol 2001, 75:7913–7924.
32. Gripon P, Le Seyec J, Rumin S, Guguen-Guillouzo C: Myristylation of the
hepatitis B virus large surface protein is essential for viral infectivity.
Virology 1995, 213:292–299.
33. Resh MD: Fatty acylation of proteins: new insights into membrane
targeting of myristoylated and palmitoylated proteins. Biochim Biophys
Acta 1999, 1451:1–16.
doi:10.1186/1743-422X-10-63
Cite this article as: Niedre-Otomere et al.: Posttranslational modifications
and secretion efficiency of immunogenic hepatitis B virus L protein
deletion variants. Virology Journal 2013 10:63.
